DBV Technologies (DBVT) Net Equity Issued and Repurchased (2020 - 2026)
DBV Technologies (DBVT) posted quarterly Net Equity Issued and Repurchased of -$100000.0 for Q2 2026, down 100.09% year-on-year from $116.9 million in Q2 2025, and down 100.11% on a QoQ basis from $89.1 million in Q1 2026.
DBV Technologies (DBVT) Net Equity Issued and Repurchased (2020 - 2026) Analysis & Trends
DBV Technologies (DBVT) has reported Net Equity Issued and Repurchased for 7 consecutive years, with -$100000.0 the latest figure, recorded in Q2 2026.
- Quarterly Net Equity Issued and Repurchased fell 100.09% year-over-year to -$100000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $247.8 million (up 110.84% YoY) and the FY2025 annual result came in at $275.7 million, up 43386.75% from the prior year.
- Net Equity Issued and Repurchased eased to -$100000.0 in Q2 2026 per DBVT's latest filing, from $89.1 million in the prior quarter.
- Over the last five years, Net Equity Issued and Repurchased for DBVT reached as high as $195.3 million in Q2 2022 and fell as low as -$864000.0 in Q3 2023.
- A 5-year average of $50.8 million and a median of $36000.0 in 2025 frame the typical range for Net Equity Issued and Repurchased.
- Annual changes were most pronounced in 2022 — Net Equity Issued and Repurchased soared 25866.76% — and 2026, when it slumped 100.09%.
- Year by year, Net Equity Issued and Repurchased stood at -$261000.0 in 2022, then soared by 107.28% to $19000.0 in 2023, then surged by 3236.84% to $634000.0 in 2024, then jumped by 24942.59% to $158.8 million in 2025, then plunged by 100.06% to -$100000.0 in 2026.
- According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered -$100000.0, $89.1 million, and $158.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 163.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 141.90 Mn |
| 10 | DBV Technologies | 267.50 Mn | 92.60 Mn | - | -100,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -100,000.00 |
| Jun 30, 2026 | -100,000.00 |
| Mar 31, 2026 | 89.10 Mn |
| Mar 31, 2026 | 89.10 Mn |
| Dec 31, 2025 | 158.77 Mn |
| Dec 31, 2025 | 158.77 Mn |
| Sep 30, 2025 | 36,000.00 |
| Sep 30, 2025 | 36,000.00 |
| Jun 30, 2025 | 116.90 Mn |
| Jun 30, 2025 | 116.90 Mn |
| Dec 31, 2024 | 634,000.00 |
| Dec 31, 2024 | 634,000.00 |
| Dec 31, 2023 | 19,000.00 |
| Dec 31, 2023 | 19,000.00 |
| Sep 30, 2023 | -864,000.00 |
| Sep 30, 2023 | -864,000.00 |
| Dec 31, 2022 | -261,000.00 |
| Dec 31, 2022 | -261,000.00 |
| Sep 30, 2022 | -538,000.00 |
| Sep 30, 2022 | -538,000.00 |